Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06211049
Other study ID # AgnoMed
Secondary ID 2023-503688-41-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 12, 2023
Est. completion date March 31, 2025

Study information

Verified date March 2024
Source Bionorica SE
Contact Kundeninfoservice
Phone +49918123190
Email info@bionorica.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this Phase III study, the herbal product Vitex agnus-castus BNO 1095 20 mg will be tested. The sponsor would like to find out if treatment with Vitex agnus-castus BNO 1095 20 mg may improve the cramping pain before or during menstruation (primary dysmenorrhea) (without an organic cause) in women and if this treatment is safe. It is tested, if the pelvic pain and other symptoms during menstruation improve in patients who are treated with Vitex agnus-castus BNO 1095 20 mg and if therefore the standard treatments for primary dysmenorrhea, for example pain relief medications will not have to be increased. The study has 2 treatment groups. Patients in one group will receive Vitex agnus-castus BNO 1095 20 mg, and patients in the other group will receive a placebo. Placebo tablets look like Vitex agnus-castus BNO 1095 20 mg tablets but have no active ingredient. Patients will be randomly assigned (like tossing a coin) to one of the 2 groups (this process is called randomization). The chance for the patients to receive Vitex agnus-castus BNO 1095 is 50%. Neither the patients nor the investigators know which product the patients are taking (this method is known as "double-blind").


Description:

This is a randomized, placebo-controlled, double-blind, multicenter, phase III clinical trial to investigate the efficacy and safety of investigational medicinal product (IMP) Vitex agnus-castus BNO 1095 20 mg in women with primary dysmenorrhea. The clinical trial will be conducted in Austria, Czech Republic, Germany, Hungary, Poland and Sweden. About 390 patients will be screened so that about 300 patients (150 patients per treatment group) will be randomized. Vitex agnus-castus BNO 1095 20 mg is extracted from the fruits of the plant Vitex agnus-castus also called monk's pepper or chaste tree. Vitex agnus-castus BNO 1095 20 mg is currently marketed for the treatment of the premenstrual syndrome (PMS) which means repeated occurrence of physical, behavioral and psychological symptoms the days before the onset of menstruation, but it is not authorized for the treatment of primary dysmenorrhea. The study has 2 treatment groups. Patients in one group will receive Vitex agnus-castus BNO 1095 20 mg, and patients in the other group will receive a placebo. Patients will be randomly assigned 1:1 to one of the 2 groups. The chance to receive Vitex agnus-castus BNO 1095 is 50%. The study is double blinded, neither the patients nor the investigators know which product the patients are taking. The study will last about 7 months for each patient. There will be 5 visits at the study site, and in addition the patients will receive 3 phone calls from the study site. On average, each study site visit will take about 2 hours and each phone call about half an hour. The trial will include 3 phases: a screening and run-in phase of up to 2 menstrual cycles, a treatment phase of 4 menstrual cycles and a follow-up phase of 1 menstrual cycle. The length of each phase depends on the length of women's menstrual cycle. If their menstrual cycle is 28 days, the screening and run-in phase will take up to 59 days (slightly more than 2 menstrual cycles), the treatment phase 113 days (about 4 menstrual cycles), and the follow-up phase 28 days (1 menstrual cycle). The main objective of this study is to determine if primary dysmenorrhea improves in women treated with Vitex agnus-castus BNO 1095 20 mg compared to placebo over a treatment duration of 3 menstrual cycles (cramping windows of Cycles 3-5). Vitex agnus-castus BNO 1095 20 mg or placebo tablets are taken orally (means by mouth) once a day during the treatment phase. If a patient usually takes pain relief medication for primary dysmenorrhea, the patient is allowed to continue taking this pain relief medication during study participation. The patients will complete the dysmenorrhea daily diary (DysDD) every day in the evening. Depending on her bleeding status, the diary includes questions about menstrual bleeding, pieces of sanitary protection used, severity of the worst pain or cramps in the pelvic area on a numerical rating scale (NRS), intake of pain relief medication, and impact on daily life in an electronic diary (handheld device). Additionally, the dysmenorrhea associated symptoms nausea, vomiting, diarrhea, fatigue, weakness, fainting, and headache will be assessed by the patients on a NRS in the electronic diary on Days 1-3 of the menstrual cycle. Migraine will be assessed by the investigator at the clinical trial visits. The patient and investigator will assess the efficacy of treatment on a 5-point verbal rating scale at the end of treatment and at the end of the study (EoS).


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: 1. Women aged 18-49 years who have the capacity for consenting 2. Patient has been informed of the nature, scope, and relevance of the clinical trial, voluntary agrees in participation and the trial provisions, and has duly signed the approved informed consent form (ICF) 3. Diagnosed primary dysmenorrhea 4. If patients take pain relief medication for primary dysmenorrhea, this medication should be taken unchanged with regard to application form and kind of medication including strength during the Screening as well as during the first three treatment cycles. Note: Medication (drugs) for primary dysmenorrhea as mono- or combination therapy in form of tablets/capsules regularly used by the patient before Screening is allowed to be used as standard pain relief medication during the trial apart from non-medication methods. A complete list of allowed pain relief medication is attached to the protocol. This medication should be taken by the patient at least for 1 cycle before Screening guaranteeing a stable intake of this medication in total for 3 cycles before randomization. 5. Patients with a regular menstrual cycle duration of =24 to =38 days 6. Patients agreeing to use one of the following contraception methods throughout the trial: 1. Bilateral tubal occlusion 2. Vasectomized partner (provided that the partner is the sole sexual partner of the woman and has received medical assessment of the surgical success) 3. Sexual abstinence Abstinence is only accepted as true abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal) is not an acceptable method of contraception 4. Male or female condom with or without spermicide 5. Cap, diaphragm, or sponge with spermicide Exclusion Criteria: A patient will not be eligible for inclusion if any of the following criteria applies: 1. Non-menstruating women 2. Clinically diagnosed secondary dysmenorrhea (e.g., fibroids, uterine adenomyosis, endometriosis, pelvic inflammation, ovarian pathologies, or other pelvic diseases) 3. Dysmenorrhea resulting from the use of an intrauterine device 4. Use of hormonal contraceptives (oral, intravaginal, transdermal, injectable, implantable), intrauterine device, or intrauterine hormone-releasing system within 6 months prior to the trial and not willing to waive it during the entire trial period 5. Any surgical treatments in the past (e.g., due to myoma) that may cause pain, adhesions or scarring in the lower abdomen Note: Further diagnostic examination (e.g., laparoscopy for differential diagnosis, exclusion of endometriosis) if deemed necessary by the investigator will be outside the trial protocol and reimbursement 6. Known or suspected gastrointestinal or urological conditions that may cause abdominal and/or pelvic pain, such as colitis, appendicitis, irritable bowel syndrome, cholelithiasis, interstitial cystitis, cystitis, urolithiasis, and other conditions that, according to the investigator's judgement, are not suitable for the trial 7. Known or suspected gynecological complaints e.g., premenstrual abdominal pain, deep dyspareunia, uterine fibroids and polyps, chronic pain (abdominal, urogenital), or backpain 8. Known instable diseases e.g., psychiatric, cardiovascular, or endocrine disorders 9. Body mass index <18.5 or >34.9 kg/m² at Screening 10. Positive gonorrhea, syphilis and/or chlamydia test at Screening 11. Current or past estrogen sensitive cancer or pituitary disorder that, in the investigator's opinion, would make the patient not suitable for the trial 12. Women who are breastfeeding, pregnant (positive pregnancy test at Screening), or planning to become pregnant during the trial 13. Fewer than 3 menstrual cycles before Screening following delivery, abortion, miscarriage, or lactation 14. Current severe physical or mental illness 15. Patient does not agree to avoid daily smoking 16. History of alcohol, drug, or medicine abuse within 1 year prior to Screening, or positive for drugs or medicines of abuse in the laboratory analysis performed at Screening 17. Patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption 18. Hypersensitivity to Vitex agnus-castus, lactose or any of the excipients of the IMP or to any ingredients of the standard pain relief medication 19. Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities 20. Employees of the sponsor or employees or relatives of the investigator 21. Legal incapacity or limited legal capacity 22. Patients not able to follow trial instructions or assessments or to participate in the trial for the whole duration of approximately 7 months or unable to understand written and verbal instruction, in particular regarding the risks and inconveniences that the patients will be exposed to during participation in the clinical trial 23. Participation in another interventional clinical trial during the last month before Screening 24. Use of Vitex agnus-castus containing preparation or product within the last 3 months before Screening 25. Current intake or intake within the last 4 weeks before Screening of dopamine agonists, dopamine antagonists, estrogens, or antiestrogens that would make the patient not suitable for the trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vitex agnus-castus BNO 1095 (20 mg)
1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
Placebo
1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).

Locations

Country Name City State
Austria Medizinische Universität Innsbruck, Department Frauenheilkunde, Universitätsklinik für Gynäkologische Endokrinologie und Reproduktionsmedizin Innsbruck
Austria Medizinische Universität Wien, Universitätsklinik für Frauenheilkunde, Klinische Abteilung für Gynäkologische Endokrinologie und Reproduktionsmedizin Wien
Czechia Centrum ambulantní gynekologie a primární péce s.r.o. Brno Stred
Czechia Fakultní nemocnice Brno, Gynekologickoporodnická Klinika, Centrum asistované reprodukce CAR 01 Brno Brno Stred
Czechia GYNEKOLOGIE CHEB s.r.o. Cheb
Czechia NEUMED gynekologická ambulance s.r.o Olomouc
Czechia Centrum gynekologické rehabilitace s.r.o Písek
Czechia MUDr. Martina Marešová Rosenbergová s.r.o. Plzen
Czechia Gyncare MUDr. Michael Švec s.r.o. Plzen 2-Slovany
Germany Praxis Dr. Noel Aachen
Germany Klinische Forschung Berlin-Mitte GmbH Berlin
Germany Frauenarztpraxis Dipl. med. Andrea Heweker, Praxis für Gynäkologie Bernburg
Germany Klinische Forschung Dresden GmbH Dresden
Germany Praxis Geseke Geseke
Germany Frauenarztpraxis Dr. Inka Kiesche Halle
Germany Frauenarzt-Praxis Dr. med. Klaus Peters Hamburg
Germany Klinische Forschung Hamburg GmbH Hamburg
Germany Klinische Forschung Hannover Mitte GmbH Hannover
Germany Praxis Dirk-Toralf Baerens Ilsede
Germany Klinische Forschung Karlsruhe GmbH Karlsruhe
Germany Klinische Forschung Schwerin GmbH Schwerin
Germany Frauenarzt in Stolberg - Wolfgang Clemens Stolberg
Hungary Clinexpert Kft. Budapest
Hungary Óbudai Egészségügyi Centrum Kft. Budapest
Hungary Zatik Med Kft. Debrecen
Hungary BKS Research Kft. Hatvan
Hungary AXON Kereskedelmi Es Szolgaltato Kft. Kecskemét
Hungary IPR Hungary Kft. Miskolc
Poland Centrum Medyczne Mikolowska dr Adam Sipinski Katowice
Poland Silmedic Sp. z o.o. Katowice
Poland Centra Medyczne Medyceusz Sp. z o.o. Lódz
Poland Nzoz Profi-Med Lublin
Poland Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji, Klinika Poloznictwa, Chorób Kobiecych i Ginekologii Onkologicznej Warszawa
Sweden Danderyds Sjukhus AB (Hospital), Clinical Trials Unit, Dept of obstetrics and gynecology Danderyd
Sweden Karolinska University Hospital, WHO-centre Stockholm
Sweden Umeå University, Dep. of Clinical Sciences, Obstetrics and Gynecology Umeå

Sponsors (2)

Lead Sponsor Collaborator
Bionorica SE FGK Clinical Research GmbH

Countries where clinical trial is conducted

Austria,  Czechia,  Germany,  Hungary,  Poland,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Proportion of patients with treatment-emergent adverse events (TEAEs), TEAEs related to the IMP, serious TEAEs related to the IMP, and TEAEs leading to premature discontinuation of the IMP The number of patients with TEAEs, TEAEs related to the IMP, serious TEAEs related to the IMP and TEAEs leading to premature discontinuation of the IMP will be determined. From Baseline (28 days prior to randomization) until Visit 5 (Day 141).
Other Assessment of change in safety laboratory parameters analyzed from blood samples (hematology) Proportion of participants with changes in hematology safety laboratory test results will be assessed. Hematology safety parameters which will be analyzed from patients' blood samples include:
Platelets, hemoglobin, hematocrit, white blood cell count total and differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), red blood cell count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC).
Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of change in safety laboratory parameters analyzed from blood samples (biochemistry) Proportion of participants with changes in safety laboratory test results will be assessed. Biochemistry safety parameters which will be analyzed from patients' blood samples include:
Liver: aspartate aminotransferase, alanine aminotransferase, gammaglutamyl transferase, alkaline phosphatase, bilirubin total; Kidney: urea (blood urea nitrogen calculated), creatinine, uric acid, glomerular filtration rate (Cockcroft and Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation), creatine clearance (Cockcroft-Gault) Other: total protein, potassium, sodium, calcium, creatine phosphokinase, glucose, chloride, inorganic phosphorous, lactate dehydrogenase, triglycerides, cholesterol total, albumin.
Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other Assessment of change in vital signs: systolic and diastolic blood pressure Number of participants with changes in systolic and diastolic blood pressure will be assessed. Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of change in vital signs: pulse Number of participants with changes in pulse will be assessed. Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other Assessment of change in vital signs: body temperature Number of participants with changes in body temperature will be assessed. Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other Assessment of change in vital signs: body height Number of participants with changes in body height will be assessed. Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other Assessment of change in vital signs: body weight Number of participants with changes in body weight will be assessed. Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other Assessment of change in physical examination of the genitourinary system: speculum examination Number of participants with changes in speculum examination findings will be assessed. Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of change in physical examination of the genitourinary system: bimanual examination Number of participants with changes in bimanual examination findings will be assessed. Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of change in physical examination: palpation of the breast Number of participants with changes in palpation of the breast findings will be assessed. Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of investigator's and patient's tolerability using a 5-point verbal rating scale The tolerability will be assessed by investigator and patient using a 5-point verbal rating scale: Very good = 0 (no side effects; no limitation of work and leisure activities due to side effects or adverse reactions); Good = 1 (hardly any side effects; hardly any limitation of work and leisure activities due to side effects or adverse reactions); Moderate = 2 (mild side effects; slight limitation of work and leisure activities due to side effects or adverse reactions); Poor = 3 (distinct side effects; distinct limitation of work and leisure activities due to side effects or adverse reactions); Very poor = 4 (severe side effects; work and leisure activities not possible due to side effects or adverse reactions). Visits 4 (Day 113) and 5 (Day 141).
Other Number of participants with absolute and relative changes in blood hormone concentrations Absolute and relative changes from Baseline in blood hormone concentration will be analyzed using laboratory tests. Changes from Baseline (28 days prior to randomization) to the Visits 2 (Day 57), 3 (Day 85) and 4 (Day 113).
Other Assessment of change in blood cytokine concentrations Absolute and relative changes from Baseline in cytokine concentration will be analyzed using Enzyme-linked Immunosorbent Assays (ELISA). Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of change in metabolome parameters (only for optional sub-study) Absolute and relative changes from Baseline in metabolome parameters assessed in the optional sub-study will be analyzed. Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of change in lipidome parameters (only for optional sub-study) Absolute and relative changes from Baseline in lipidome parameters assessed in the optional sub-study will be analyzed. Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other Assessment of change in microbiome parameters (only for optional sub-study) Absolute and relative changes from Baseline in microbiome parameters assessed in the optional sub-study will be analyzed. Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Primary Proportion of patients who respond to treatment defined as: a) a =3-point reduction in the peak pelvic pain score and b) no increase in the number of standard pain relief medication Response to treatment will be determined by comparing the peak pelvic pain score (using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) made during the cramping window of Cycle 5 with those made at Baseline and by comparing the assessments of number of tablets or capsules of standard pain relief medication taken during the cramping window of Cycle 5 with those taken at Baseline. Change from Baseline (28 days prior to randomization) to the cramping window of Cycle No. 5 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Proportion of patients who respond to treatment defined as: a) a =3-point reduction in the peak pelvic pain score and b) no increase in the number of standard pain relief medication in the cramping window of Cycles 3, 4, and 6 compared to Baseline Response to treatment will be determined by comparing the peak pelvic pain score (using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) made during the cramping window of Cycles No. 3, 4 and 6 with those made at Baseline and by comparing the assessments of number of tablets or capsules of standard pain relief medication taken during the cramping window of Cycles No. 3, 4 and 6 with those taken at Baseline. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Proportion of patients with a =3-point reduction in the peak pelvic pain score and a decrease in the number of standard pain relief medication The =3-point reduction in the peak pelvic pain score using an 11-point numeric rating scale (NRS; scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) will be assessed and the amount of standard pain relief medication taken will be evaluated to investigate the efficacy of the study drug. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Proportion of patients with a peak pelvic pain score of "0" or "1" and no use of standard pain relief medication Peak pelvic pain score of "0" or "1" using an 11-point numeric rating scale (NRS; scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) and no use of standard pain relief medication during the cramping window of Cycles 3, 4, 5, and 6 will be evaluated. At the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of change of peak pelvic pain score The peak pelvic pain score will be assessed using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) assessments and compared to Baseline. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of the sum of the pelvic pain scores The pelvic pain scores assessed during the cramping windows (4 days) of Cycles 3, 4, and 5 (i.e., 12 assessments in total) using an 11-point numeric rating scale (NRS; scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) will be summed up. At the cramping windows of Cycles No. 3, 4 and 5 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of the change of the sum of the pelvic pain scores The pelvic pain scores assessed during the cramping window using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) assessments will be summed up per cycle and compared to Baseline. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of the change in the number of days with pelvic pain The number of days with pelvic pain will be calculated as sum of the days with a pelvic pain above 0 on the 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) during the respective cramping window and compared to Baseline. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of change in the number of standard pain relief medication taken The number of standard pain relief medication will be calculated as sum of the tablets/capsules taken during the respective cramping window and compared to Baseline. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of change in the number of days with use of standard pain relief medication The number of days with use of standard pain relief medication will be calculated as sum of days with intake of standard pain relief medication during the respective cramping window and compared to Baseline. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Proportion of patients with no use of standard pain relief medication The number of patients who did not use any standard pain relief medication will be determined.
The analysis will be performed for all patients as well as for the subgroup of patients who took any standard pain relief medication during the cramping window of Cycle 5.
At the cramping window of Cycle No. 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of change in the impact on the patient's daily life The impact of pelvic pain or cramps on the patient's daily life including paid work, work around the home, or school work will be assessed on a 5-point scale being part of the dysmenorrhea daily diary (DysDD) assessments (0=not at all, 1=slightly, 2=moderately, 3=quite a bit, 4=extremely). The assessments made during each cramping window will be summed up.
The impact on physical activities, social or leisure activities, and sleep will be analyzed analogously. The missed time of paid work, work around the home, or school work will be summed up for the cramping window and tabulated by treatment group and cycle.
Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Investigator's and patient's overall assessment of efficacy using a 5-point verbal rating scale The treatment efficacy will be assessed by the investigator and the patient using a 5-point verbal rating scale with the following 5 categories: very good, good, moderate, poor, very poor. Visits 4 (Day 85) and 5 (Day 113)
Secondary Assessment of change in the intensity of menstrual bleeding The intensity of the menstrual bleeding will be assessed on a 5-point scale (0=no bleeding, 1=very light bleeding or spotting, 2=light bleeding, 3=moderate bleeding, 4=heavy bleeding). The assessments made during each cramping window will be summed up. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of change in the number of pieces of sanitary protection used The number of pieces of sanitary protection used will be assessed on a 4-point scale (0=0, 1=1 piece, 2=2 pieces, 3=3 or more pieces). The assessments made during Day 1 to Day 3 of the cramping window will be summed up. Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of change in the severity of nausea, vomiting, diarrhea, fatigue, weakness, fainting, and headache on a numeric rating scale (NRS) The analysis is based on the peak NRS score of days 1, 2, and 3 per cycle (11-point NRS scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)). Change from Baseline (28 days prior to randomization) to the Days 1-3 of Cycles No. 3, 4, 5 and 6 (each cycle is 28 days).
Secondary Proportion of patients with migraine The number of patients with migraine will be determined. The chance of patients having a migraine episode since the last clinical trial visit will be analyzed. At Baseline (28 days prior to randomization) and Visits 0, 1, 2, 3, 4 and 5 (i.e., Days 1, 29, 57, 85, 113 and 141)
Secondary Assessment of change in the peak pelvic pain score The change in peak pelvic pain score using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed. At the cramping windows of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of relative change in the peak pelvic pain score The relative change in peak pelvic pain score using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed. At the cramping window of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of change in the number of standard pain relief medication taken The number of standard pain relief medication will be calculated as sum of tablets/capsules taken during the cramping window. The change from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed. At the cramping window of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary Assessment of relative change in the number of standard pain relief medication taken The number of standard pain relief medication will be calculated as sum of tablets/capsules taken during the cramping window. The relative change from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed. At the cramping window of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
See also
  Status Clinical Trial Phase
Completed NCT03594916 - Efficacy of Transcranial Direct Current Stimulation for Severe Primary Dysmenorrhea N/A
Completed NCT03608215 - Neuromodulatary Efficacy of Transcranial Direct Current Stimulation in Severe Refractory Primary Dysmenorrhea N/A
Not yet recruiting NCT04541134 - Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea Phase 3
Completed NCT04083131 - Sense of Coherence and Primary Dysmenorrhea in High School Girls in Finistere, France
Not yet recruiting NCT05448027 - Low Versus High Intensity Laser Therapy on Primary Dysmenorrhea N/A
Completed NCT04662814 - Extracorporeal Shock Wave Therapy for Dysmenorrhea N/A
Recruiting NCT05771753 - Comparison of Core Stabilization and Dynamic Stretching Exercises in Primary Dysmenorrhea N/A
Not yet recruiting NCT04665661 - Aerobic Exercise for Primary Dysmenorrhea N/A
Completed NCT03290066 - Effectiveness of Kinesiotaping in Primary Dysmenorrhea N/A
Completed NCT03593850 - Music for Pain in Primary Dysmenorrhea N/A
Completed NCT04235595 - Comparison of the Effects of TENS and CTM on Primary Dysmenorrhea N/A
Completed NCT05081869 - Investigation of the Effect of Online Yoga Based Exercise Program on Women With Primary Dysmenorrhea N/A
Not yet recruiting NCT06398990 - The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea N/A
Completed NCT02026206 - Low-level Light Therapy for Primary Dysmenorrhea Phase 3
Completed NCT05686460 - Effect of Hegu Point Ice Massage and Music in Dysmenorrhea N/A
Not yet recruiting NCT06052722 - The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders N/A
Completed NCT04119011 - Probiotics in Women With Primary Dysmenorrhoea Phase 1/Phase 2
Active, not recruiting NCT05938660 - Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students. N/A
Completed NCT04856280 - Kinesiological Taping and Aerobic Exercise in Women With Primary Dysmenorrhea: N/A
Completed NCT02602522 - Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea Early Phase 1